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Adults with GH deﬁciency are known to exhibit reduced sweating. Whether sweating capacity is impacted in obese subjects
with impaired GH secretion have not previously been investigated. The main objective was to investigate sweat secretion rate
and the GH-IGF-I axis in obese subjects before and after weight loss. Sixteen severely obese women (BMI, 40.6 ± 1.1kg/m2)
were investigated before and after a diet-induced weight loss. Sixteen age-matched nonobese women served as controls. The
obese subjects presented the characteristic decreased GH release, hyperinsulinaemia, increased FFA levels, and impaired insulin
sensitivity, which all were normalised after diet-induced weight loss of 30 ± 5kg. Sweat secretion rates were similar comparing
obese and nonobese subjects (78 ± 10 versus 82 ± 9mg/30 minutes) and sweat secretion did not change after a diet-induced
weight loss in obese subjects. We conclude that although obese subjects have markedly reduced GH release and impaired IGF-I
levels, sweat secretion rate is found to be normal.
1.Introduction
Sweating capacity as measured by sweat secretion rates has
been reported reduced in adult patients with GH deﬁciency
[1–4] as well as in children with GH deﬁciency (GHD)
and GH insensitivity syndromes [5, 6]. Furthermore, sweat
secretion has been found correlated to circulating IGF-I
levels [1, 4, 7], and GH deﬁciency have been reported to
have a profound eﬀect on thermoregulation [2, 8]. These
observations in patients with GHD suggest that GH have a
role in thermal regulation, via an eﬀect on sweating capacity,
and the reduced sweating is part of the abnormalities
observed in patients with GHD [7, 9], as well as that some
of the positive eﬀects reported following GH replacement
therapy might be due to a normalization of sweat secretion
[7]. Normal sweating is of importance for maintaining
correct temperature regulation and if disturbed can cause
signiﬁcant discomfort. The mechanism of GH action on
sweating is not clear; however, GH receptors have been
demonstrated on sweat glands, and GH may function as a
trophic factor for sweat glands [10]. It has been suggested
that GH hyper- and hyposecretory states result in changes
in the growth and metabolic status of sweat glands, with
alterations in sweat gland innervation [4] and a reduced
number of sweat glands has been reported in adults with
GHD [11].
Adults with GHD are characterised by perturbations
in body composition, lipid metabolism, and cardiovascular
risk proﬁle [12]. It is well established that adult GHD
usually is accompanied by an increase in fat accumulation
and these changes in body composition are associated with
metabolic derangements including insulin resistance [12].
Obese subjects as adults with GHD have multiple endocrine
abnormalities including insulin resistance, severely sup-
pressed spontaneous and stimulated GH release [13–15],
and impaired circulating IGF-I levels [13]. The obesity-
associated decrease in GH secretion is partially or fully
recovered after diet-induced or surgical-induced reduction
of fat mass [13, 14]. In addition, sweat gland activity is
reported impaired in obese subjects [16], and heat-waves
can cause major discomfort to obese subjects. Although,
the many similarities between adults with GHD and obese2 International Journal of Endocrinology
subjects are well recognised, there are no published data
available on sweating capacity in obese subjects and the
relationship to the GH-IGF-I axis. Thus, the primary aim
of the study was to investigate sweat secretion rate in obese
subjects as well as in relation to the GH-IGF-I axis and the
impact of a diet-induced weight loss on sweating. Secondary
objective was to relate sweat secretion and GH-IGF-I to
endocrine abnormalities including hyperinsulinaemia, and
elevated FFA often observed both in obese subjects and
adults with GHD.
2. Methods
2.1. Subjects. We studied 16 obese female subjects, with a
mean age of 29.5 ± 1.4 years and with a mean BMI of 40.6 ±
1.1kg/m 2; these were morbidly obese subjects, who under-
went a diet-induced weight loss program. At the conclusion
of the weight-loss program, 8 obese women completed the
weight loss program with a weight-loss of approximately
30% of their initial body weight corresponding to a weight-
loss of 30 ± 5kg and a mean body mass index (BMI) of
27.0 ± 1.4kg/m 2. The remaining 8 obese women dropped
out during the study due to lack of motivation. The control
group consisted of 16 normal lean female subjects with a
mean age of 27.0 ± 1.1 years and a mean BMI of 23.2 ±
0.4kg/m 2. All the subjects were nondiabetic and pre-
menopausal. All the subjects gave informed consent. The
revised Helsinki 2 Declaration was observed, and the study
was approved by the Copenhagen Municipal Ethical Com-
mittee.
2.2. Weight-Loss Study. The obese subjects participated in a
structured, outpatient weight-loss program where the goal
was to achieve ideal body weight. During the initial phase
the subjects consumed a commercial very-low-calorie diet
that provided 1.6megajoule (MJ)/day. The patients visited
the outpatient clinic weekly for body weight measurements
and nutrition counselling. When body weight had decreased
to approximately 130% of ideal body weight, the patients
were instructed to discontinue the 1.6MJ/day diet and
begin consuming 5.0MJ/day diet of normal food items.
During this period, the patients used the diet and nutrition
materials that had been supplied to them and discussed
during the counselling sessions. When ideal body weight
was achieved or when no further weight could be lost, the
patients were instructed to begin consuming a basic 8.0MJ/d
diet (15% protein, 55% carbohydrate, and 30% fat) which
was individually adjusted for each patient to obtain energy
balance. Energy intake was further adjusted down or up
for each subject on a weekly basis (during weekly dietary
counselling) to reach a ﬁnal, stable body weight (e.g., if body
weight began to increase, daily energy intake was reduced).
Samplinginthepostobesepatientswasperformedafterbody
weight had remained stable (±1.5kg) for ≥1 month after
switching to the last diet.
2.3. Twenty-Four-Hour Study. For each 24-h sampling pe-
riod the subjects were admitted to the metabolic ward at
07:30AM. after an overnight fast. A cannula (Viggo AB,
Vingmed, Denmark) was placed in a forearm vein. Blood
withdrawal commenced 30 min after venipuncture through
anonthrombogenic catheter(Carmeda;ViggoAB,Vingmed,
Denmark) inserted through the cannula and connected to
an automatic constant withdrawal pump (withdrawal rate
was 3.5mL/h). Collection tubes were changed at 20-min
intervals over the following 24-h period giving a series of
72 sequential samples for each subject. The technique allows
the participants to sleep during the night and to move freely
around during the day. For GH measurements all 72 serum
samples were assayed (total n = 5760). The basal blood
samples were taken after the subjects had fasted overnight.
2.4. Analyses. Evaluation of sweat secretion was performed
as previously described [17]. In the resting subject, sweating
was induced on the ﬂexor side of the distal forearm by ion-
tophoresis with 0.2% pilocarpine chloride, using a current
of 2mA for 5 minutes. Two ﬁlter papers (Whatman Ashless
Roundﬁlters, diameter 2cm) were soaked in pilocarpine
solution and were positioned underneath the electrode. Two
quadrangular negative electrodes (size 3×3cm)wereplaced
on the ﬂexor side of the upper arm. After 5 minutes, the
area of iontophoresis was rinsed with deionized water and
61% ethanol and dried thoroughly. Sweat was collected
for a 30 minute-period with the three ﬁlter papers sealed
with roundel of plastic tape to prevent evaporation. Sweat
mass was measured by weighing ﬁlter paper (Mettler Scales,
precision ±0.1mg) before and after collection.
Serum GH concentration was determined using a time-
resolved immunoﬂuorometric assay (TR-IFMA, PerkinElm-
er LifeSciences, T¨ urku, Finland). IGF-I was determined in
acid-ethanol-extracted serum by a speciﬁc radioimmunoas-
say [18]. Insulin was determined using an enzyme-linked
two-site immunoassay as described by Andersen et al.
[19]. FFA concentrations were determined by a previously
described microﬂuorometric method [20].
2.5. Calculations. T h ea r e au n d e rt h ec u r v e( A U C )o f2 4 -
hour GH release was estimated above the zero level as pre-
viously described [21]. The Quantitative Insulin Sensitivity
Check Index (QUICKI) was calculated from the fasting
insulin and glucose values; QUICKI = 1/[log insulin +
log glucose] as described by Katz et al. [22]. Body mass index
was calculated as weight (kg)/height (m2). Body weight was
measured to the nearest 0.1kg with an electronic scale (Seca
070; Seca, Copenhagen). Twenty-four-hour GH release and
IGF-I data have previously been reported separately [23].
2.6. Statistics. Mann-Whitney rank sum test was used when
comparing data between diﬀerent groups (unpaired data).
Wilcoxon signed rank test was applied when comparing
paired data from the previously obese subjects to the same
eight subjects in the prediet obese state. Linear regression
analysis was performed to identify independent eﬀects of
hormonal factors (FFA, insulin, and IGF-I) on 24-h GH
release. Unless otherwise stated, all data are expressed as
mean ± SEM. The level of statistical signiﬁcance was set at
P<0.05.International Journal of Endocrinology 3
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Figure 1: Sweat secretion rate. Columns represent (left to right)
levels in non-obese (n = 16), obese (n = 16), and previously obese
subjects (n = 8).
3. Results
3.1. Weight-Loss Study. At the conclusion of the weight-loss
program, the 8 obese women that completed the weight loss
program had lost approximately 30% of their initial body
weight (30 ± 5kg). The remaining 8 obese women dropped
out during the study due to lack of motivation.
3.2.SweatSecretion. Sweatsecretionwassimilarinobeseand
non-obese women (75 ±9v e r s u s7 3±5mg/30min), and no
change in sweat secretion occurred after diet-induced weight
loss (Figure 1).
3.3. 24-Hour GH Release and IGF-I Levels. Twenty-four-
hour GH release was found to be reduced in obese women
compared to non-obese women (Figure 2). A signiﬁcant
increase in GH levels was observed after weight loss, and no
signiﬁcant diﬀerence was present between previously obese
and non-obese women (Figure 2). Basal levels of IGF-I were
signiﬁcantly lower in obese women at preweight loss com-
pared to non-obese women and a signiﬁcant increase was
observed in IGF-I levels after weight loss, and no signiﬁcant
diﬀerence was present between previous obese and non-
obese women (Table 1). Twenty-four-hour GH release and
IGF-I data have previously been reported separately [23].
3.4. Insulin and FFA. F F Aa sw e l la si n s u l i nl e v e l sw e r ef o u n d
elevated (Table 1). No signiﬁcant diﬀerence in FFA or insulin
levels was present after weight loss between previously obese
and non-obese women (Table 1).
3.5. Insulin Sensitivity. Insulin sensitivity estimated by the
QUICKI formula was decreased in obese women compared
to non-obese women. A signiﬁcant increase in insulin
sensitivity was observed after weight loss, and no signiﬁcant
diﬀerence was present between previously obese and non-
obese women (Table 1).
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Figure 2: Twenty-four-hour GH release. Columns represent (left to
right) levels in non-obese (n = 16), obese (n = 16), and previously
obese subjects (n = 8).
Table 1: Twenty-four-hour GH, basal levels of insulin, FFA, IGF-I
levels, and insulin sensitivity in 16 obese, 8 previously obese, and 16
non-obese.
Non-obese Obese Previously
obese
24-hour AUC GH
(mU/L·24h) 341 ±41 99 ±23∗ 299 ±81‡
IGF-I (µg/L) 308 ±18 220 ±21∗ 330 ±73‡
FFA (meq/L) 0.55 ±0.07 0.80±0.07∗∗ 0.63 ±0.08‡
Insulin (pmol/L) 46.8 ±3.68 1 .9 ±7.8∗ 43.3 ±9.1‡
QUICKI (no
units) 0.38 ±0.01 0.33 ±0.01∗ 0.39 ±0.01‡
∗P<0.001 Obese versus non-obese.
∗∗P<0.05 Obese versus non-obese.
‡P<0.05 Obese versus previously obese.
Table 2: Correlations between 24-hour GH release, IGF-I, FFA
insulin,andinsulinsensitivityinallsubjects(non-obese,obese,and
previously obese subjects).
24-hour GH release
Insulin r =− 0.59; P<0.001
QUICKI r = 0.72; P<0.00001
FFA r =− 0.10; ns
IGF-I r = 0.10; ns
3.6. Relationships between Insulin, Insulin Sensitivity, FFA,
IGF-I, and 24-Hour GH Release. Regression analysis per-
formed considering non-obese, obese, and previously obese
subjects showed a signiﬁcant positive correlation between
insulin sensitivity and 24-hour GH release (Table 2).
4. Discussion
We have previously reported 24-h GH release and IGF-I
levels to be impaired in obese subjects and normalised after4 International Journal of Endocrinology
diet-induced weight loss [23]. The novel data reported now
imply that although GH deﬁciency and obesity in adults
feature many similarities, we did not observe an impact on
sweating capacity in the obese subjects despite markedly
reduced spontaneous GH release and impaired circulating
IGF-I levels. Thus, the subnormal sweat secretion rate in
adults with GH deﬁciency reported in previous studies [1–4]
as well as the positive correlations between circulating IGF-I
levels and sweat secretion rate in these patients [1]m a yb e
speciﬁcally related to severe GH deﬁciency and not impaired
GH-IGF-I axis per se. One explanation for the diﬀerence
could be damage to the thermoregulatory centre in these
patients with pituitary disease; however, parts of the GH-
IGF axis seem to be present in human sweat glands [10, 24].
It could be speculated whether the normal sweat secretion
observedinobesesubjectswithimpairedGH-IGF-Iaxisadds
further evidence that the criterion for the diagnosis of GHD
in obese patients is complex. The mechanism behind the role
ofGHandIGF-Iinsweatglandfunctionremainsspeculative,
and it cannot be ruled out that other factors than the GH-
IGF-I axis in obese subjects are involved in the more profuse
sweatsecretionobserved,althoughgoodcorrelationbetween
whole body sweat secretion and regional sweat secretion rate
has been reported [17].
A secondary objective of the study was to relate sweat
secretion and GH-IGF-I to hyperinsulinaemia and elevated
FFA often observed in obese subjects. Insulin and FFA are
twoof the main peripheral signals proposed tobe interwined
with the impaired GH release observed in obesity. We found
no relationship between sweat secretion and insulin, or
FFA levels. However, our data suggest that the decreased
spontaneous 24-hour GH release observed in obesity seems
related to the concomitant hyperinsulinaemia and insulin
sensitivity rather than elevated FFA levels.
It has previously been reported that hyperinsulinaemia
results in suppressed pituitary GH release [25–27]. In
addition, circulating elevated FFAs have been suggested to
be involved in the mechanism behind the hyposomatropism
observed in obesity [28, 29]. In the present study, circulating
FFA levels were signiﬁcantly increased in obese subjects as
reported by others; however, FFA levels were apparently not
associated with the impaired physiological GH release. The
improved GH response to stimulation tests in obese subjects
pretreated with acipimox has been suggesting elevated FFA
levels to be involved in the mechanism behind the GH
hyposecretion observed in obesity [28, 29]. However, it
is noteworthy that acipimox-induced decrease in FFA did
not have an impact on physiological GH secretion [28].
Considering that acipimox is known to strongly reduce
serum insulin in obese patients [30], it is speculated
whether reductions in insulin levels per se might explain
the magnitude of the acipimox-induced improvement in GH
response. This can likely be explained as when insulin levels
are signiﬁcantly increased, insulin’s role overcomes the eﬀect
of FFA on the GH release.
In conclusion, we did not observe an impact on sweating
capacity in the obese subjects despite markedly reduced
spontaneous GH release and impaired circulating IGF-I
levels.
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